5 completed, 4 terminated, 1 withdrawn. 10 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 5, Terminated 4, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
Follow anecortave acetate: new trials by email Literature Review of anecortave acetate trials Research Report on anecortave acetate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Anecortave Acetate Safety in Patients With Open-Angle Glaucoma or Ocular Hypertension Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/mL, Anecortave Acetate Sterile Suspension, 75 mg/mL - Open-angle Glaucoma, Oular Hypertension | Phase 2 / Phase 3 | Completed | Alcon Research | 201 | 2008-06-01 | 2012-11-28 |
| A Multi-Dose Study With a Treatment for Open-Angle Glaucoma Anecortave Acetate, Placebo - Open-Angle Glaucoma | Phase 2 / Phase 3 | Withdrawn | Alcon Research | 2008-05-01 | 2012-05-30 | |
| Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD) Anecortave Acetate 15 mg sterile suspension, Anecortave Acetate Vehicle - Macular Degeneration, Maculopathy, Age-Related | Phase 3 | Completed | Alcon Research | 291 | 2007-01-01 | 2012-11-28 |
| Anecortave Acetate Risk Reduction Trial (AART) Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/mL, Anecortave Acetate Vehicle - AMD | Phase 3 | Terminated | Alcon Research | 36 | 2006-09-01 | 2012-11-28 |
| Anecortave Acetate Risk-Reduction Trial (AART) Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/ML, Anecortave Acetate Vehicle - AMD | Phase 3 | Terminated | Alcon Research | 24 | 2005-05-01 | 2012-11-28 |
| Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD) Anecortave Acetate Sterile Suspension, 30 mg/mL, Anecortave Acetate Sterile Suspension, 60 mg/mL, Anecortave Acetate Vehicle - Macular Degeneration | Phase 3 | Completed | Alcon Research | 240 | 2005-03-01 | 2012-11-28 |
| Anecortave Acetate Risk-Reduction Trial (AART) Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg, Anecortave Acetate Vehicle - Dry AMD | Phase 3 | Terminated | Alcon Research | 2596 | 2004-03-01 | 2012-11-28 |
| Open-Label Posterior Juxtascleral Injections of Anecortave Acetate 15mg Dose for Long Term Use in Patients With AMD Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL - Macular Degeneration | Phase 3 | Terminated | Alcon Research | 111 | 2003-06-01 | 2013-09-16 |
| An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD anecortave acetate - Macular Degeneration, Maculopathy, Age-Related | Phase 3 | Completed | Alcon Research | 2003-03-01 | 2012-11-29 | |
| Phase 3 Study to Evaluate Anecortave Acetate vs. Visudyne for the Treatment of the Wet Form of AMD Anecortave Acetate 15 mg sterile suspension, Photodynamic Therapy (PDT) - Macular Degeneration | Phase 3 | Completed | Alcon Research | 530 | 2002-06-01 | 2014-07-01 |
Macular Degeneration (5) · Glaucoma, Open-Angle (2)
Alcon Research (10)
United States (7) · India (1)
Terry Wiernas, PhD (3) · Patricia Zilliox (1) · Patricia Zilliox, Ph.D. (1)